Puma Biotechnology, Inc. (PBYI)

Puma Biotechnology, Inc. (PBYI) is a healthcare company (biotechnology) based in the United States. The share price is $7.14, down 2.72% on the day, which values the company at $369.13M. Price as of 18 Nov 2026, 11:07 UTC, from Yahoo Finance.

Key facts

Share price
$7.14−2.72% today
Market value
$369.13M
P/E ratio
15.5×last 12 months
Forward P/E
20.4×
Funk Score
54/100
Against its own history
Well above its usual priceusual price $4.93
200-week average
$4.7052% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Puma Biotechnology, Inc. in more detail

PBYI trades at 15.5× its last twelve months' earnings, 20.4× next year's expected earnings, 1.6× sales. Measured against its own history, the price is 45% above what its usual multiples would imply ($4.93) — well above its usual price. It sits 52% above its 200-week average of $4.70.

Over the last five fiscal years Puma Biotechnology, Inc. has compounded revenue 0.3% a year, free cash flow 124.8% a year. Its Funk Score is 54 out of 100 (financial strength 6.1, profitability 7.6, growth 4.2, value 3.5, each out of 10).

In its favour: More cash than debt; High return on invested capital. Worth checking: Altman Z in the distress zone; Share count keeps rising.

Puma Biotechnology, Inc. (PBYI): questions and answers

What is PBYI's P/E ratio?

Puma Biotechnology, Inc. trades at 15.5× its last twelve months' earnings and 20.4× next year's expected earnings. At its fiscal year-ends over the past 3 years the P/E ranged from 4.9× to 9.8×, with a median of 9.6×.

What is Puma Biotechnology, Inc.'s market cap?

Puma Biotechnology, Inc. is valued at $369.13M at a share price of $7.14.

Is PBYI overvalued or undervalued?

Against its own history, PBYI is well above its usual price: the price is 45% above the $4.93 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is PBYI above its 200-week moving average?

Yes. PBYI is 51.9% above its 200-week average of $4.70. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Puma Biotechnology, Inc. growing?

Over the last five fiscal years Puma Biotechnology, Inc.'s revenue grew 0.3% a year.

Does PBYI pay a dividend?

Puma Biotechnology, Inc. does not currently pay a regular dividend.

Cite this page

Funkfolio, “Puma Biotechnology, Inc. (PBYI) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/PBYI

Underlying data: Yahoo Finance; company filings with the SEC.